A PYMNTS Company

23 million euros cleared for R&D of Novartis vaccines

 |  May 8, 2012

The European Commission has cleared €23 million of proposed funding for Novartis Italy to develop vaccines in developing countries. After its assessment for R&D&I aid (research, development and innovation), the Commission has found that the support addresses a genuine market failure and stimulates research in the EU. Novartis’ project will create innovative vaccines at affordable prices. The project is also supported by the Gates Foundation and is expected to incur €76.9 million in R&D over five years.

Full content: EC Press Release


Related contentRevision of the EU Competition Rules on Cooperation in Research & Development and Production: Scope for Further Improvement (Axel Gutermuth, Arnold & Porter)

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.